storage conditions is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-28. Numbers and descriptions here follow the published literature rather than marketing material.
Copper binds to the peptide through the histidine imidazole nitrogen and the terminal amino group, forming a stable square-planar complex. Binding constants reported for copper(II) with GHK are high, so the peptide competes effectively for copper in solution. The complex absorbs visible light, which gives solutions a blue to violet colour. Whether the metal-free peptide has a distinct biological function of its own is still an open question; some work treats it mainly as a copper delivery vehicle, while other work reports peptide-specific effects.
The compound was first isolated from human plasma in the 1970s by Loren Pickart, who later described copper-binding activity in liver and other tissues. Early reports focused on its presence in blood and its ability to carry copper between proteins. Commercial and cosmetic use of the term 'copper peptide' has since broadened, and labels rarely distinguish GHK-Cu from other copper-binding fragments. This naming overlap makes literature searching harder, because cosmetic ingredient lists, supplier catalogues and laboratory papers use different vocabularies for the same molecule.
Material described in research and cosmetic supply chains is typically a synthetic peptide supplied as a lyophilized powder. Purity is commonly reported through chromatographic separation, often at 95 percent or higher, while copper content is confirmed by separate elemental analysis. Batch variation in color and solubility can reflect residual counter-ions, moisture, or partial oxidation of the peptide. Because the complex is not a single regulatory entity, specifications differ between suppliers and are not standardized internationally.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, its terminal amino group, and a deprotonated amide nitrogen, creating a stable chelate ring. The resulting complex carries a distinctive blue to blue-violet color, which arises from copper d-d electronic transitions. In the solid state it is usually handled as a powder, while in solution the complex can dissociate and re-form depending on pH and competing ligands. The name copper tripeptide-1 is widely used in ingredient listings.
| Property | Value | Notes |
|---|---|---|
| Sequence | Gly-His-Lys | Three amino acids; histidine supplies the main copper-binding nitrogen |
| Bound metal | Copper(II) | Coordination is described as square-planar around the metal centre |
| Appearance | Blue to violet solid | Colour originates from copper d-d electronic transitions |
| Solubility class | Freely soluble in water | Aqueous solutions are often slightly acidic |
| Common synonyms | Copper tripeptide, Cu-GHK | Ingredient lists may say only 'copper peptide' without giving the sequence |
Discovery of GHK is generally attributed to work in the 1970s that isolated a plasma factor influencing liver cell behavior. Subsequent studies identified the copper-binding tripeptide and its ability to chelate copper with high affinity. Early reports linked the complex to wound healing and tissue remodeling in animal models. The free peptide and the copper-bound form have different properties, so the two are distinguished in the literature. Whether endogenous GHK-Cu serves a single primary physiological role remains an open question.
The molecular weight and charge of GHK-Cu depend on the pH and the number of coordinated ligands. At neutral pH, the peptide typically binds one copper ion, but ternary complexes with other biomolecules can form. Spectroscopic methods such as electron paramagnetic resonance and circular dichroism are used to study the coordination environment. Reports on the exact geometry vary because the complex is dynamic in solution. Researchers often use synthetic GHK-Cu rather than extracted material to control stoichiometry and purity.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Copper content is measured separately by techniques such as inductively coupled plasma mass spectrometry or atomic absorption. Amino acid analysis confirms the peptide sequence after hydrolysis. Because the metal and the peptide can be quantified independently, a complete certificate of analysis normally reports both values rather than a single purity figure. This separation of measurements is important when comparing suppliers.
Solid GHK-Cu appears as a blue to blue-violet powder, and the colour is a direct consequence of copper coordination. The complex dissolves readily in water and in many polar solvents, while the free peptide behaves differently. Solubility in nonpolar media is low, which limits its use in oil-based systems. Solutions are typically prepared fresh because the dissolved form is more exposed to hydrolysis and to loss of the metal ion than the dry powder. Working concentrations are usually low, and preparation notes often specify the solvent and the order of addition.
Handling practices for the solid material emphasise low temperature and dryness. The lyophilised or powdered form is typically kept at refrigerator or freezer temperatures together with a desiccant. Working solutions are often prepared fresh, because repeated freeze-thaw cycles and extended storage may alter the complex. Glass or inert plastic containers are preferred over materials that could leach metal ions into the preparation. Such practices follow general peptide conventions rather than substance-specific regulations.
Analytical verification commonly relies on high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Spectroscopic methods such as UV-visible absorption and electron paramagnetic resonance can probe the metal centre itself, since the d9 configuration of copper(II) produces characteristic signals. Elemental analysis or plasma-based techniques quantify copper content. Because each method reports a different aspect of the same sample, purity figures are most meaningful when the technique and its detection wavelength are stated alongside the value.
==== Endocrine actions ==== Valproic acid has been found to be an antagonist of the androgen and progesterone receptors, and hence as a nonsteroidal antiandrogen and antiprogestogen, at concentrations much lower than therapeutic serum levels. In addition, the drug has been identified as a potent aromatase inhibitor, and suppresses estrogen concentrations. These actions are likely to be involved in the reproductive endocrine disturbances seen with valproic acid treatment. Valproic acid has been found to directly stimulate androgen biosynthesis in the gonads via inhibition of histone deacetylases and has been associated with hyperandrogenism in women and increased 4-androstenedione levels in men. High rates of polycystic ovary syndrome and menstrual disorders have also been observed in women treated with valproic acid.
=== Indigenous Affairs === In the April 2019 budget, funding for the Ministry of Indigenous Affairs was cut in half. Minister Rickford released a May 9, 2019 statement saying that the Ontario Government was "committed to do everything in its authority to support the relocation" of the Kashechewan First Nation. which is located north of Fort Albany, Ontario on the James Bay coast. The community has had flooding and infrastructure problems for many years and in April 2019, had to evacuate 2,500 members by plane when a state of emergency was called again. APTN reported, in the presence of 300 community members, both the federal and provincial governments signed the Framework Agreement with Kashechewan First Nation to commit to moving the reserve. The federal Minister of Indigenous Services Seamus O'Regan said the relocation process would probably take about eight years to complete.
== Effects of the Closure == Madera Community Hospital was the only hospital within a 30 mile radius, thus the closure caused 160,000 Madera residents to not have access to a local emergency room. Many people were faced with driving the 45 minutes to one of the neighboring towns or not receiving proper treatment. Unfortunately, this decision was already made for residents without access to a vehicle or public transportation. Other hospitals in the Central Valley were then stressed by the pressures of taking on all of the patients who would have previously been treated in Madera, which caused significant increases in emergency room wait times. Private ambulance companies from other counties pitched in to help take calls from Madera to transport residents to other hospitals such as Saint Agnes Medical Care (Fresno) and Community Regional Medical Center (Fresno). Not only were the patients redirected, 772 employees across the four locations were laid off when the hospital shuttered its doors.
Peptide therapeutics are peptides or polypeptides (oligomers or short polymers of amino acids) which are used for the treatment of diseases. Naturally occurring peptides may serve as hormones, growth factors, neurotransmitters, ion channel ligands, and anti-infectives; peptide therapeutics mimic such functions. The presence of a peptide structure in a drug or chemical is not enough information to determine its effectiveness or its safety, or to draw conclusions about the overall effectiveness or safety of other substances sharing that particular structure. In 2025 and 2026, off-label peptide use and the use of unapproved peptides became popular on social media. However, these peptides have unconfirmed safety and efficacy, and are not a recognised medical treatment.
Controlled animal and human studies showed that caffeine (energy drinks) in combination with alcohol increased the craving for more alcohol more strongly than alcohol alone. These findings correspond to epidemiological data that people who consume energy drinks generally showed an increased tendency to take alcohol and other substances.
Sources: en.wikipedia.org
=== Africa === South Africa: In South Africa, the BCG Vaccine is given routinely at birth, to all newborns, except those with clinically symptomatic AIDS. The vaccination site is in the right arm. Morocco: In Morocco, the BCG was introduced in 1949. The policy is BCG vaccination at birth, to all newborns. Kenya: In Kenya, the BCG Vaccine is given routinely at birth to all newborns.
== Licenses == As of 2025, a plurality (39%) of models released on Hugging Face used the permissive Apache 2.0 License. Some models, such as the source-available Llama 3, have licenses that grant some of the benefits of open-source licenses, but also contain legal restrictions that deter some companies from using those models, as the companies fear a future lawsuit or a change in the terms and conditions. Some of the same fears also exist in the large number of smaller models that do not specify a license.
== Factors/pathways == Cells can detect and react to mechanical stimuli in a variety of ways. One method is through the interaction of E-cadherin presented on the cell membrane. As these receptors interact and are pulled or pushed, tension can be created, leading to a change in the conformation of alpha-catenin bound to B-catenin on the intracellular portion of E-cadherin. This causes the recruitment of vinculin and leads to a change in actin conformation and in the orientation of the cell. Another signaling pathway important in a cell's response to mechanical stimuli is the Wnt planar cell polarity (PCP) pathway. This noncanonical pathway involves the activation of Rho and Rac families of GTPases, which are essential in reorganizing the cytoskeleton in preparation for cell migration. When cells collide, localized signaling of the PCP pathway leads to a change in the polarity of the cell, redirecting the cell in a different direction. Different cellular receptors are important in cellular mechanotransduction involved in contact with a substrate such as the extracellular matrix (ECM). For example, many cell types express a5b1 integrin on their membranes, which can bind to a major ECM component called fibronectin. This leads to an accumulation of integrins in the area of contact with the ECM, attaching the ECM to the cytoskeleton of the cell and allowing for migration to occur along the ECM through tension at the points of attachment (called focal adhesions, FA) and subsequently the dismantling of FAs as the cell moves along.
=== Light === Herbarium specimens are sensitive to visible light and ultraviolet radiation, which can cause fading of biological pigments (fading or shifts in color) and/or damage to chemical bonds (weakened or embrittled).
Sources: en.wikipedia.org
1333: Thomasia de Mattio, Italian physician, mentioned in Pope Sixtus IV edict regarding physicians and surgeons. fl. 1335: Polisena da Troya, licensed Neapolitan surgeon. d. 1366: Jeanne d'Ausshure, French surgeon. fl. 1374: Floreta La-Noga, Aragonese physician. fl. 1376: Virdimura of Catania, Jewish-Sicilian physician. fl. 1380: Bellayne Gallipapa, Zaragoza, Aragonese-Jewish physician. fl. 1384: Dolcich Gallipapa, Lleida, Catalan-Jewish physician. fl. 1384: Juana Sarrovia, Barcelona, Catalan physician. fl. 1387: Na Pla Gallipapa, Zaragoza, Aragonese-Jewish physician. late 13th century: Margherita di Napoli, Napolitan oculist active in Frankfurt-am-Main. fl. 1390: Dorotea Bucca, Italian professor of medicine. 1386–1408: Maesta Antonia, Florentine physician. 14th century: Abella, Italian physician. 14th century: Mercuriade, Italian physician and surgeon. fl. 1400: Antonia Daniello, Florentine-Jewish physician. fl. 13th century: Brunetta de Siena, Italian-Jewish physician. fl. 13th century: Caterina of Florence, Florentine physician. fl. 1411: Peretta Peronne, also called Perretta Petone, French surgeon. fl. 1415: Constance Calenda, Italian surgeon specializing in diseases of the eye. fl. 1438: Jeanne de Cusey, French barber-surgeon. fl. 1460: Marguerite Saluzzi, Napolitan licensed herbalist physician. fl. 1479: Guillemette du Luys, French royal surgeon. d. 1498: Gentile Budrioli (or Gentile Cimieri), Italian astrologer and herbalist. 15th century: Clarice di Durisio, Italian physician. 15th century Francesca, muller de Berenguer Satorra, Catalan physician. c.
=== February === 1 February – Scottish Water confirms that water bills will increase by 8.8% from April. Honshu, a seven-year-old male Japanese macaque who escaped from the Highland Wildlife Park at Kincraig, is recaptured after five days on the run. 3 February – A bus driver, subsequently named as Keith Rollinson, dies in hospital at Elgin following an assault at a bus station in the town the previous evening. A 15-year-old boy is subsequently arrested and charged with murder. Transport Scotland has put forward proposals for road tunnels linking parts of the Western Isles, and linking Mull to the mainland. 4 February – The Scottish Information Commissioner, which oversees Scotland's freedom of information laws, launches a probe into the Scottish Government's use of informal messaging such as WhatsApp after "significant practice concerns" were raised by the UK COVID-19 Inquiry. The Met Office issues a yellow warning for floods for western and northern Scotland as the country experiences heavy rainfall. 6 February – Elena Whitham resigns from the post of Minister for Drugs and Alcohol Policy for health reasons. 8 February – Michael Matheson resigns as Scotland's Health Secretary ahead of the publication of a report into £11,000 of data roaming charges accrued by his Parliamentary iPad. He is replaced by Neil Gray. The Scottish Government announces a rise in the minimum unit price for alcohol from 50p to 65p from April, subject to parliamentary approval. Edinburgh City Council says that 200 people have been fined since it introduced a ban on pavement parking on 29 January.
At the highest assessed dose in castrated male rats, levator ani weight was increased to around 140% of that of gonadally intact controls, whereas prostate weight was only increased to around 45% of that of intact controls. The tissue selectivity of LGD-4033 was independent of local tissue drug concentration, suggesting that its selectivity was intrinsic. The muscle-stimulating effects of LGD-4033 have also been confirmed in humans in preliminary clinical trials. The data also allow comparison between different SARMs and other AR agonists. In a phase 1 clinical trial in 76 healthy young men, 1 mg/day LGD-4033 increased lean body mass by 1.2 kg after 3 weeks of treatment. For comparison, enobosarm, another SARM, increased lean body mass by 1.3 kg at a dose of 3 mg/day after 12 weeks in healthy elderly men and postmenopausal women. It was concluded that the employed dose of LGD-4033 produced similar increases in lean body mass compared to enobosarm despite a substantially shorter treatment period. In a phase 2 clinical trial in 108 women and men with hip fracture, LGD-4033 increased lean body mass by 4.8% at 0.5 mg/day, 7.2% at 1 mg/day, and 9.1% at 2 mg/day after 12 weeks of treatment. For comparison, lean body mass with enobosarm 3 mg/day after the same time period of 12 weeks increased by about 0.30% at 0.1 mg/day, 0.40% at 0.3 mg/day, 1.2% at 1 mg/day, and 3.1% at 3 mg/day, with only the latter change achieving statistical significance.
In August 2004, Palatin signed an agreement with King Pharmaceuticals to co-develop bremelanotide in the US and jointly license it outside the US; King paid Palatin $20 million upfront. Palatin conducted Phase II trials of intranasal bremelanotide in both female sexual dysfunction (FSD) and male erectile dysfunction (ED), but these trials were halted by the FDA in 2007, due to increased blood pressure in clinical trial subjects; Palatin stopped development of the intranasal formulation in 2008. Four trials were conducted in ED, the last being a Phase IIb published in 2008. King terminated the co-development agreement shortly after the FDA halted the trials. The drug was then reformulated to be delivered by injection and trials continued in FSD. A phase II dose-finding trial in FSD in which the drug was administered 45 minutes before sex showed promise at the highest dose and only transient signs of high blood pressure; two Phase III trials were launched at the end of 2014. Palatin launched the Phase III trials with bremelanotide administered via an autoinjector. In 2014, Palatin licensed European rights to bremelanotide to Gedeon Richter Plc. for around $10 million, and Palatin received a milestone payment of around $3 million when it started the Phase III trials in the US. In September 2016, Palatin and Gedeon Richter terminated that agreement. In November 2016, Palatin announced results of the Phase III trials, and shortly thereafter began seeking a partner to complete development in the US.
isomeric genes Two or more genes that are equivalent and redundant in the sense that, despite coding for distinct gene products, they each result in the same phenotype when set within the same genetic background. If several isomeric genes are present in a single genotype they may be either cumulative or non-cumulative in their contributions to the phenotype.
Sources: en.wikipedia.org
The letters GHK are the one-letter codes for glycine, histidine and lysine, the three amino acids in the peptide. The suffix Cu indicates that the peptide is bound to a copper ion, normally copper(II).
The free tripeptide and its copper complex have been measured in human plasma, saliva, urine and some tissue extracts. Reported concentrations vary widely between studies, and the role of the complex in normal physiology remains partly unresolved.
The plain peptide lacks the metal, so its charge, colour and binding behaviour differ. The copper complex is blue and carries a bound copper ion, while the metal-free form is colourless and has different solution chemistry.
It is a complex of the tripeptide glycyl-L-histidyl-L-lysine with a copper(II) ion. The peptide coordinates the metal through its histidine, amino terminus, and an amide nitrogen. It is often listed simply as copper tripeptide-1.